UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 209

Sortiert nach

First-Line Immunotherapy for Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2022-02, Vol.40 (6), p.586-597

2022

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant immunotherapy for NSCLC - does treating earlier mean treating better?

Nature reviews. Clinical oncology, 2022-01, Vol.19 (1), p.7-8

2022

Link zum Volltext

Verfügbarkeit prüfen

Upfront osimertinib - winner takes it all?

Nature reviews. Clinical oncology, 2020-04, Vol.17 (4), p.202-203

2020

Link zum Volltext

Verfügbarkeit prüfen

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Cancer treatment reviews, 2020-11, Vol.90, p.102105-102105, Article 102105

2020

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer

Current opinion in oncology, 2017-03, Vol.29 (2), p.97-104

2017

Link zum Volltext

Verfügbarkeit prüfen

Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

BMC medicine, 2017-03, Vol.15 (1), p.55-55, Article 55

2017

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Journal of thoracic oncology, 2020-06, Vol.15 (6), p.914-947

2020

Link zum Volltext

Verfügbarkeit prüfen

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

Clinical cancer research, 2016-12, Vol.22 (24), p.5983-5991

2016

Link zum Volltext

Verfügbarkeit prüfen

The efficacy of immune checkpoint inhibitors in thoracic malignancies

European respiratory review, 2021-12, Vol.30 (162), p.200387

2021

Link zum Volltext

Verfügbarkeit prüfen

Precision oncology: separating the wheat from the chaff

ESMO open, 2018, Vol.3 (6), p.e000446-e000446, Article e000446

2018

Link zum Volltext

Verfügbarkeit prüfen

Editorial: Understanding the Interplay Between the Tumor Immune Microenvironment and Genetic Alterations in Thoracic Malignancies

Frontiers in oncology, 2022-03, Vol.12, p.871544-871544

2022

Link zum Volltext

Verfügbarkeit prüfen

Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK -Rearranged Non-Small Cell Lung Cancer Patients

Cancer research (Chicago, Ill.), 2017-05, Vol.77 (9), p.2222-2230

2017

Link zum Volltext

Verfügbarkeit prüfen

APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients. EORTC 1613

Clinical lung cancer, 2017-09, Vol.18 (5), p.583-588

2017

Link zum Volltext

Verfügbarkeit prüfen

Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?

Therapeutic Advances in Medical Oncology, 2022, Vol.14, p.17588359221113268-17588359221113268

2022

Link zum Volltext

Verfügbarkeit prüfen

Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer

PloS one, 2017-08, Vol.12 (8), p.e0183319-e0183319

2017

Link zum Volltext

Verfügbarkeit prüfen

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer

Cancers, 2020-12, Vol.12 (12), p.3625

2020

Link zum Volltext

Verfügbarkeit prüfen

Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

BMC medicine, 2017-04, Vol.15 (1), p.82-82, Article 82

2017

Link zum Volltext

Verfügbarkeit prüfen

Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma

European radiology, 2020-09, Vol.30 (9), p.5021-5028

2020

Link zum Volltext

Verfügbarkeit prüfen

Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases

JTO clinical and research reports, 2021-01, Vol.2 (1), p.100096, Article 100096

2021

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers

Cancers, 2020-11, Vol.12 (11), p.3459

2020

Link zum Volltext

Verfügbarkeit prüfen

Befotertinib—a viable alternative in EGFR-mutant advanced NSCLC?

The lancet respiratory medicine, 2023-10, Vol.11 (10), p.857-859

2023

Link zum Volltext

Verfügbarkeit prüfen

Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy

Clinical cancer research, 2020-10, Vol.26 (19), p.5068-5077

2020

Link zum Volltext

Verfügbarkeit prüfen

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Journal of thoracic oncology, 2023-05, Vol.18 (5), p.576-586

2023

Link zum Volltext

Verfügbarkeit prüfen

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient

Journal of thoracic oncology, 2015-08, Vol.10 (8), p.e72-e73

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 209

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(187)
Mit Volltextzugriff
(195)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(128)
Life Sciences & Biomedicine
(125)
Oncology
(102)
Humans
(82)
Respiratory System
(47)
Lung Neoplasms - Drug Therapy
(39)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(37)
Lung Cancer
(37)
Male
(30)
Immunotherapy
(27)
Female
(26)
Lung Neoplasms - Genetics
(26)
Chemotherapy
(23)
Aged
(22)
Carcinoma, Non-Small-Cell Lung - Genetics
(22)
Middle Aged
(22)
Mutation
(20)
Tumors
(20)
Cancer
(19)
Carcinoma, Non-Small-Cell Lung - Pathology
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

First-Line Immunotherapy for Non-Small-Cell Lung Cancer

Adjuvant immunotherapy for NSCLC - does treating earlier mean treating better?

Upfront osimertinib - winner takes it all?

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer

Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

The efficacy of immune checkpoint inhibitors in thoracic malignancies

Precision oncology: separating the wheat from the chaff

Editorial: Understanding the Interplay Between the Tumor Immune Microenvironment and Genetic Alterations in Thoracic Malignancies

Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK -Rearranged Non-Small Cell Lung Cancer Patients

APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients. EORTC 1613

Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay

Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer

Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma

Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases

Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers

Befotertinib—a viable alternative in EGFR-mutant advanced NSCLC?

Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient

Suchergebnisse filtern